KRAS and neoplasm: Based on the design of this clinical trial in which we expected uptake in ≥1 of 10 or ≤7 of 10 patients (power >90%, type I error <5%), our results indicate that tumor uptake of 89Zr-cetuximab may be used to predict clinical benefit of cetuximab in patients with wt K-RAS mCRC, which should be further validated in a larger cohort of patients.